CN114075289B - 抗cd73的抗体及其用途 - Google Patents

抗cd73的抗体及其用途 Download PDF

Info

Publication number
CN114075289B
CN114075289B CN202110939980.1A CN202110939980A CN114075289B CN 114075289 B CN114075289 B CN 114075289B CN 202110939980 A CN202110939980 A CN 202110939980A CN 114075289 B CN114075289 B CN 114075289B
Authority
CN
China
Prior art keywords
sequence
antibody
seq
amino acid
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110939980.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114075289A (zh
Inventor
王忠民
金小平
李百勇
夏瑜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akeso Pharmaceuticals Inc
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Publication of CN114075289A publication Critical patent/CN114075289A/zh
Application granted granted Critical
Publication of CN114075289B publication Critical patent/CN114075289B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202110939980.1A 2020-08-17 2021-08-16 抗cd73的抗体及其用途 Active CN114075289B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010828886 2020-08-17
CN2020108288864 2020-08-17
CN2020111525189 2020-10-23
CN202011152518 2020-10-23

Publications (2)

Publication Number Publication Date
CN114075289A CN114075289A (zh) 2022-02-22
CN114075289B true CN114075289B (zh) 2024-07-02

Family

ID=80283259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110939980.1A Active CN114075289B (zh) 2020-08-17 2021-08-16 抗cd73的抗体及其用途

Country Status (7)

Country Link
US (1) US20240218074A1 (https=)
EP (1) EP4197555A4 (https=)
JP (1) JP2023538369A (https=)
CN (1) CN114075289B (https=)
AU (1) AU2021326889A1 (https=)
CA (1) CA3191745A1 (https=)
WO (1) WO2022037531A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021087463A1 (en) * 2019-11-01 2021-05-06 Corvus Pharmaceuticals, Inc. Immunomodulatory anti-cd73 antibodies and uses thereof
WO2023206242A1 (zh) * 2022-04-28 2023-11-02 江苏中新医药有限公司 无钩状效应的抗人cd73单克隆抗体
CN117304316A (zh) * 2022-06-22 2023-12-29 复旦大学 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001474A (zh) * 2014-11-21 2017-08-01 百时美施贵宝公司 抗cd73抗体及其用途
CN110869393A (zh) * 2018-03-07 2020-03-06 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2016131950A1 (en) * 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
IL250579B2 (en) * 2014-10-10 2023-05-01 Innate Pharma blocking cd73
DK3218406T4 (da) * 2014-11-10 2024-12-09 Medimmune Ltd Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
EP3218407A1 (en) * 2014-11-11 2017-09-20 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
CN104558137A (zh) * 2015-01-15 2015-04-29 浙江欧诗漫生物股份有限公司 一种珍珠蛋白的制备方法及该方法制备得到的水溶性珍珠蛋白和酸溶性珍珠蛋白
US11130817B2 (en) * 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
WO2017100670A1 (en) * 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
KR20230038311A (ko) * 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
US11180554B2 (en) * 2016-12-13 2021-11-23 Astellas Pharma Inc. Anti-human CD73 antibody
EP3383916B1 (en) * 2017-01-24 2022-02-23 I-Mab Biopharma US Limited Anti-cd73 antibodies and uses thereof
WO2018215535A1 (en) * 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
CN118307674A (zh) * 2017-06-22 2024-07-09 诺华股份有限公司 针对cd73的抗体分子及其用途
TWI823906B (zh) * 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
KR102804816B1 (ko) * 2018-03-09 2025-05-09 페인스 테라퓨틱스 인코포레이티드 항-cd73 항체 및 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001474A (zh) * 2014-11-21 2017-08-01 百时美施贵宝公司 抗cd73抗体及其用途
CN110869393A (zh) * 2018-03-07 2020-03-06 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途

Also Published As

Publication number Publication date
CA3191745A1 (en) 2022-02-24
JP2023538369A (ja) 2023-09-07
AU2021326889A1 (en) 2023-03-23
EP4197555A1 (en) 2023-06-21
US20240218074A1 (en) 2024-07-04
CN114075289A (zh) 2022-02-22
WO2022037531A1 (zh) 2022-02-24
EP4197555A4 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
CN114075289B (zh) 抗cd73的抗体及其用途
CN114380915B (zh) 抗cd73的抗体及其用途
ES3001154T3 (es) Anticuerpo monoclonal anti-PD1, composición farmacéutica del mismo y uso del mismo
US12595302B2 (en) CLDN18.2 binding molecule
EP4169948A1 (en) Anti-cd73 antibody and use thereof
CN114478768B (zh) 抗cd73的抗体及其用途
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
TW200927760A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
JP7763780B2 (ja) 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用
US12304967B2 (en) Fusion protein and use thereof
EP4253414A1 (en) Anti-tigit antibody, and pharmaceutical composition and use thereof
WO2021249542A1 (en) Antibodies binding tnfr2 and uses thereof
CN114106182B (zh) 抗tigit的抗体及其用途
CN113444177A (zh) 抗IL-1β的抗体、其药物组合物及其用途
WO2023246247A1 (zh) 药物组合物及其用途
JP2022514832A (ja) 抗ｔｉｍ－３抗体とその利用
CN117624352A (zh) 抗Tmem176b抗体、药物组合物及用途
JP2024502670A (ja) Ｇａｒｐタンパク質抗体及びその適用
HK40089235A (en) Anti-cd73 antibody and use thereof
US20240166745A1 (en) Lag-3 and pd-1/lag-3-antibodies
CN118725132A (zh) 双特异性抗体、药物组合物及用途
WO2025104253A1 (en) Anti-muc16 antibodies and uses thereof
CN119431583A (zh) 靶向cd155的抗体或抗原结合片段及其应用
HK40093009A (en) Anti-tigit antibody, and pharmaceutical composition and use thereof
TW202140551A (zh) 抗cldn18.2抗體及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant